相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Validity of chemotherapy information derived from routinely collected healthcare data: A national cohort study of colon cancer patients
Jemma M. Boyle et al.
CANCER EPIDEMIOLOGY (2021)
The Early Impact of the IDEA Collaboration Results: How the Results Changed Prescribing Practice
Timothy Iveson et al.
JNCI CANCER SPECTRUM (2021)
Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) dataset
Chloe J. Bright et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2020)
Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials
Atul Batra et al.
CLINICAL COLORECTAL CANCER (2020)
Self-reported prescribing practices in the setting of adjuvant treatment for colorectal cancer
C. Hanna et al.
ANNALS OF ONCOLOGY (2020)
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
G. Argiles et al.
ANNALS OF ONCOLOGY (2020)
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
Thierry André et al.
LANCET ONCOLOGY (2020)
Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer A Systematic Review and Meta-analysis
Devon J. Boyne et al.
JAMA NETWORK OPEN (2019)
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
A. Sobrero et al.
ANNALS OF ONCOLOGY (2018)
Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
Peng Gao et al.
BMC CANCER (2018)
Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer
Jonathan M. Loree et al.
CLINICAL COLORECTAL CANCER (2018)
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Timothy J. Iveson et al.
LANCET ONCOLOGY (2018)
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
A. Grothey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Lawrence Blonde et al.
ADVANCES IN THERAPY (2018)
Association between timing and duration of adjuvant chemotherapy and survival for colorectal cancer in korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance.
In Gyu Hwang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Real-World Evidence - What Is It and What Can It Tell Us?
Rachel E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
Yi-Jian Tsai et al.
SPRINGERPLUS (2016)
Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study
C. M. Lund et al.
ESMO OPEN (2016)
Prognostic Factors and the Role of Adjuvant Chemotherapy in Post-curative Surgery for Dukes B and C Colon Cancers and Survival Outcomes: a Malaysian Experience
Astrid Sinarti Hassan et al.
Asian Pacific Journal of Cancer Prevention (2015)
Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer
Aalok Kumar et al.
CLINICAL COLORECTAL CANCER (2015)
Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer
Caitlin C. Murphy et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Efficacy and Safety of Single Agent or Combination Adjuvant Chemotherapy in Elderly Patients With Colon Cancer: A Canadian Cancer Institute Experience
Christina A. K. Kim et al.
CLINICAL COLORECTAL CANCER (2014)
Complicated postoperative recovery increases omission, delay and discontinuation of adjuvant chemotherapy in patients with Stage III colon cancer
L. G. M. van der Geest et al.
COLORECTAL DISEASE (2013)
Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database
Nadine J. McCleary et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial
Christophe Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer
Chung-Yuan Hu et al.
MEDICAL ONCOLOGY (2011)
Multiple imputation using chained equations: Issues and guidance for practice
Ian R. White et al.
STATISTICS IN MEDICINE (2011)
Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score
J. N. Armitage et al.
BRITISH JOURNAL OF SURGERY (2010)
Early Discontinuation but Not the Timing of Adjuvant Therapy Affects Survival of Patients With High-Risk Colorectal Cancer: A Population-Based Study
Shahid Ahmed et al.
DISEASES OF THE COLON & RECTUM (2010)
Etiology of Delays in the Initiation of Adjuvant Chemotherapy and Their Impact on Outcomes for Stage II and III Rectal Cancer
Winson Y. Cheung et al.
DISEASES OF THE COLON & RECTUM (2009)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
J. Philip Kuebler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients
M. Morris et al.
BRITISH JOURNAL OF CANCER (2007)
Immortal time bias in observational studies of drug effects
Samy Suissa
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studies
Henrik Toft Sorensen et al.
HEPATOLOGY (2006)
Duration of adjuvant chemotherapy for colon cancer and survival among the elderly
Alfred I. Neugut et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Completion of therapy by medicare patients with stage III colon cancer
Sharon A. Dobie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Capecitabine as adjuvant treatment for stage III colon cancer
C Twelves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma
K Chansky et al.
CANCER (2005)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cumulative incidence estimation in the presence of competing risks
Vincenzo Coviello et al.
STATA JOURNAL (2004)
Preoperative radiotherapy for resectable rectal cancer -: A meta-analysis
C Cammà et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
